Avalyn Pharma Bolsters Pulmonary Portfolio with $100M Series D Financing

Cambridge, MA, July 22, 2025 (Globe Newswire) -- Avalyn Pharma raised $100 million in an oversubscribed Series D round to accelerate development of its inhaled therapies for serious lung diseases. The round was led by top healthcare investors and included new board appointments to support strategic growth. The financing strengthens Avalyn’s position in advancing treatments for pulmonary conditions with high unmet need.

Read full article here.